Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Nephrology | Urology | Family Medicine
 Disease Category: Prostate Cancer
Location: United States, FL

Trial Information

Prostate Cancer - A Phase III, Open-Label Trial of Degarelix Intermittent Therapy vs. Continuous Androgen Deprivation Therapy with Leuprolide or Degarelix in patients with carcinoma of the prostate with biochemical failure after localized therapy

The purpose of this trial is to give Degarelix with intermittent treatment as compared to continuous androgen deprivation with regard to maintaining PSA suppression in 14 months of treatment.

Patient Inclusion Criteria:

  • Patient is at least 18 years old
  • Rising PSA after prior treatment failure of localized prostate cancer
  • CT scan, MRI or bone scan report documenting no evidence of metastatic to the bone or internal organs
  • Life expectancy of at least 15 months

Patient Exclusion Criteria:

  • Taken hormone therapy in the past 12 months prior to entering study
  • History of severe uncontrolled asthma
  • History of previous or presence of another malignancy other than prostate cancer or treated squamous/basal cell carcinoma of the skin within the last five years
  • Has an intellectual incapacity or language barriers precluding adequate understand or co-operation

Nancy Manusov, Research Recruitment Specialist
Southeastern Research Group, Inc.
2000 Centre Pointe Boulevard
Tallahassee, FL 32308
Phone: 850-201-0411
Email: nmanusov@serginc.com

View Map

Research Center Information: Southeastern Research Group, Inc.

If you would like to learn more about participating in this study, please send an email message using the form below.

Name:
Address:
City:
State:
Country:
Phone:
Email:  
Message:
 

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.